| Item Type | Name |
|
Concept
|
Oncogene Proteins, Fusion
|
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
|
Concept
|
Proto-Oncogene Proteins pp60(c-src)
|
|
Concept
|
Proto-Oncogene Proteins c-raf
|
|
Concept
|
Proto-Oncogene Proteins B-raf
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Concept
|
Oncogene Protein v-akt
|
|
Concept
|
Proto-Oncogene Proteins c-ret
|
|
Academic Article
|
BRAF and RAS mutations in human lung cancer and melanoma.
|
|
Academic Article
|
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
|
|
Academic Article
|
Loss of Rap1GAP in papillary thyroid cancer.
|
|
Academic Article
|
RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells.
|
|
Academic Article
|
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.
|
|
Academic Article
|
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
|
|
Academic Article
|
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
|
|
Academic Article
|
BRAF mutation and thyroid cancer recurrence.
|
|
Academic Article
|
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
|
|
Academic Article
|
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-na?ve RET-mutant medullary thyroid cancer.
|
|
Academic Article
|
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
|
|
Academic Article
|
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
|
|
Academic Article
|
Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer - Authors' response.
|
|
Academic Article
|
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
|
|
Academic Article
|
Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
|
|
Academic Article
|
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
|
|
Academic Article
|
pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
|
|
Academic Article
|
Reply to C. Bal et al and M. Xing.
|
|
Academic Article
|
Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.
|
|
Academic Article
|
Diagnosis and management of TRK fusion cancer.
|
|
Academic Article
|
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
|
|
Academic Article
|
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
|
|
Academic Article
|
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
|
|
Academic Article
|
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
|
|
Academic Article
|
Absence of BRAF mutations in UV-protected mucosal melanomas.
|
|
Academic Article
|
The RET/PTC3 oncogene activates classical NF-?B by stabilizing NIK.
|